144 related articles for article (PubMed ID: 38918202)
1. Stable responses to danicopan as add-on to ravulizumab in two patients with paroxysmal nocturnal hemoglobinuria.
Füreder W; Valent P
Ann Hematol; 2024 Jun; ():. PubMed ID: 38918202
[No Abstract] [Full Text] [Related]
2. Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial.
Lee JW; Griffin M; Kim JS; Lee Lee LW; Piatek C; Nishimura JI; Carrillo Infante C; Jain D; Liu P; Filippov G; Sicre de Fontbrune F; Risitano A; Kulasekararaj AG;
Lancet Haematol; 2023 Dec; 10(12):e955-e965. PubMed ID: 38030318
[TBL] [Abstract][Full Text] [Related]
3. [Japanese patient preferences between ravulizumab and eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria].
Ishiyama K; Usuki K; Ikezoe T; Gotoh A; Myren KJ; Tomazos I; Shimono A; Ninomiya H; Sakurai M; Nakao S; Nishimura JI
Rinsho Ketsueki; 2023; 64(1):9-17. PubMed ID: 36775313
[TBL] [Abstract][Full Text] [Related]
4. Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up.
Yenerel MN; Sicre de Fontbrune F; Piatek C; Sahin F; Füreder W; Ortiz S; Ogawa M; Ozol-Godfrey A; Sierra JR; Szer J
Adv Ther; 2023 Jan; 40(1):211-232. PubMed ID: 36272026
[TBL] [Abstract][Full Text] [Related]
5. Dosing Patterns of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab in the United States: A Retrospective Claims-Based Analysis.
Cheng WY; Fishman J; Yenikomshian M; Mahendran M; Kunzweiler C; Vu JD; Duh MS
Adv Ther; 2024 Jan; 41(1):413-430. PubMed ID: 37999832
[TBL] [Abstract][Full Text] [Related]
6. Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab.
Tomazos I; Sierra JR; Johnston KM; Cheung A; Brodsky RA; Weitz IC
Hematology; 2020 Dec; 25(1):327-334. PubMed ID: 32856539
[No Abstract] [Full Text] [Related]
7. Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies.
Kulasekararaj AG; Griffin M; Langemeijer S; Usuki K; Kulagin A; Ogawa M; Yu J; Mujeebuddin A; Nishimura JI; Lee JW; Peffault de Latour R;
Eur J Haematol; 2022 Sep; 109(3):205-214. PubMed ID: 35502600
[TBL] [Abstract][Full Text] [Related]
8. Exploring treatment strategies for paroxysmal nocturnal hemoglobinuria: an overview of registered clinical trials.
Peixoto VP; Prudêncio C; Vieira M
Curr Med Res Opin; 2024 May; ():1-11. PubMed ID: 38727420
[TBL] [Abstract][Full Text] [Related]
9. One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab.
Kulasekararaj AG; Hill A; Langemeijer S; Wells R; González Fernández FA; Gaya A; Ojeda Gutierrez E; Piatek CI; Mitchell L; Usuki K; Bosi A; Brodsky RA; Ogawa M; Yu J; Ortiz S; Röth A; Lee JW; Peffault de Latour R
Eur J Haematol; 2021 Mar; 106(3):389-397. PubMed ID: 33301613
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Ariceta G
Expert Rev Clin Pharmacol; 2023 May; 16(5):401-410. PubMed ID: 37128905
[TBL] [Abstract][Full Text] [Related]
11. Interim analysis of post-marketing surveillance of ravulizumab for paroxysmal nocturnal hemoglobinuria in Japan.
Usuki K; Ikezoe T; Ishiyama K; Kanda Y; Gotoh A; Hayashi H; Shimono A; Kitajima A; Obara N; Nishimura JI
Int J Hematol; 2023 Sep; 118(3):311-322. PubMed ID: 37477863
[TBL] [Abstract][Full Text] [Related]
12. Successful management of unstable angina in a ravulizumab-treated patient with paroxysmal nocturnal hemoglobinuria.
Takahashi H; Mori H; Fukatsu M; Sano T; Harada K; Oikawa M; Takeishi Y; Kimura S; Ohkawara H; Shichishima T; Ikezoe T
Fukushima J Med Sci; 2022 Dec; 68(3):175-178. PubMed ID: 36130907
[TBL] [Abstract][Full Text] [Related]
13. Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
Lee JW; Kulasekararaj AG
Expert Opin Biol Ther; 2020 Mar; 20(3):227-237. PubMed ID: 32011183
[No Abstract] [Full Text] [Related]
14. Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison.
Bhak RH; Mody-Patel N; Baver SB; Kunzweiler C; Yee CW; Sundaresan S; Swartz N; Duh MS; Krishnan S; Sarda SP
Curr Med Res Opin; 2021 Nov; 37(11):1913-1923. PubMed ID: 34445916
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab.
Kulasekararaj AG; Risitano AM; Maciejewski JP; Notaro R; Browett P; Lee JW; Huang M; Geffner M; Brodsky RA
Blood; 2021 Nov; 138(20):1928-1938. PubMed ID: 34314483
[TBL] [Abstract][Full Text] [Related]
16. Safety of current treatments for paroxysmal nocturnal hemoglobinuria.
Lee SE; Lee JW
Expert Opin Drug Saf; 2021 Feb; 20(2):171-179. PubMed ID: 33249943
[No Abstract] [Full Text] [Related]
17. Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria.
Stern RM; Connell NT
Ther Adv Hematol; 2019; 10():2040620719874728. PubMed ID: 31534662
[TBL] [Abstract][Full Text] [Related]
18. [Perioperative management of laparoscopic cholecystectomy in a patient with paroxysmal nocturnal haemoglobinuria undergoing ravulizumab treatment].
Kimura M; Nishiyama Y; Ueda H; Kitajo A; Arimatsu T; Kuboki M; Takahata A; Saito M; Sakashita C; Okada K; Umezawa Y; Nagao T; Yamamoto M; Tohda S; Tanabe M; Mori T; Nogami A
Rinsho Ketsueki; 2022; 63(4):260-264. PubMed ID: 35491214
[TBL] [Abstract][Full Text] [Related]
19. Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy.
Versino F; Fattizzo B
Int J Lab Hematol; 2024 May; 46 Suppl 1():43-54. PubMed ID: 38622956
[TBL] [Abstract][Full Text] [Related]
20. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey.
Dingli D; Matos JE; Lehrhaupt K; Krishnan S; Yeh M; Fishman J; Sarda SP; Baver SB
Ann Hematol; 2022 Feb; 101(2):251-263. PubMed ID: 34973099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]